Patents by Inventor Juergen Krause

Juergen Krause has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20230007847
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: January 25, 2022
    Publication date: January 12, 2023
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20220241415
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: September 10, 2021
    Publication date: August 4, 2022
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Protein formulations and methods of making same
    Patent number: 11191834
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: December 7, 2021
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Protein formulations and methods of making same
    Patent number: 11167030
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: November 9, 2021
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20210121567
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 29, 2021
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20210113695
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20210113694
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20190358322
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 28, 2019
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20190054171
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 21, 2019
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Fischer-tropsch synthesis
    Patent number: 10190057
    Abstract: A method (10) of synthesizing Fischer-Tropsch products (20) includes feeding a synthesis gas (30) to a moving-bed Fischer-Tropsch synthesis reactor (16) containing a Fischer-Tropsch catalyst in a moving catalyst bed and catalytically converting at least a portion of the synthesis gas (30) in the moving catalyst bed to Fischer-Tropsch products (20). The Fischer-Tropsch products (20) are removed from the moving-bed Fischer-Tropsch synthesis reactor (16). The method (10) further includes, while the moving-bed Fisher-Tropsch synthesis reactor (16) is on-line, withdrawing a portion (50) of the Fischer-Tropsch catalyst from the moving-bed Fischer-Tropsch synthesis reactor (16), adding a reactivated Fischer-Tropsch catalyst (57, 58) to the moving-bed Fischer-Tropsch synthesis reactor (16), and adding a fresh Fischer-Tropsch catalyst (60,58), in addition to the reactivated catalyst (57,58), to the moving-bed Fischer-Tropsch synthesis reactor (16).
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: January 29, 2019
    Assignee: SASOL TECHNOLOGY PROPRIETARY LIMITED
    Inventors: Richard Neil Walsh, Jean Louis Gauché, Hendrik Wilhelmus Joubert, Albertus Maritz Van Wyk, Johannes Henning Viljoen, Marcel Juergen Krause
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20180339046
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: August 7, 2018
    Publication date: November 29, 2018
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9950066
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 24, 2018
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FISCHER-TROPSCH SYNTHESIS
    Publication number: 20170321126
    Abstract: A method (10) of synthesising Fischer-Tropsch products (20) includes feeding a synthesis gas (30) to a moving-bed Fischer-Tropsch synthesis reactor (16) containing a Fischer-Tropsch catalyst in a moving catalyst bed and catalytically converting at least a portion of the synthesis gas (30) in the moving catalyst bed to Fischer-Tropsch products (20). The Fischer-Tropsch products (20) are removed from the moving-bed Fischer-Tropsch synthesis reactor (16). The method (10) further includes, while the moving-bed Fisher-Tropsch synthesis reactor (16) is on-line, withdrawing a portion (50) of the Fischer-Tropsch catalyst from the moving-bed Fischer-Tropsch synthesis reactor (16), adding a reactivated Fischer-Tropsch catalyst (57, 58) to the moving-bed Fischer-Tropsch synthesis reactor (16), and adding a fresh Fischer-Tropsch catalyst (60,58), in addition to the reactivated catalyst (57,58), to the moving-bed Fischer-Tropsch synthesis reactor (16).
    Type: Application
    Filed: October 26, 2015
    Publication date: November 9, 2017
    Inventors: Richard Neil Walsh, Jean Louis Gauché, Hendrik Wilhelmus Joubert, Albertus Maritz Van Wyk, Johannes Henning Viljoen, Marcel Juergen Krause
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9750808
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 5, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9738714
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 22, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9732152
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 15, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170158759
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 8, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170151329
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 1, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20170143828
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170145087
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes